You are viewing: UK AI in Biotechnology Market analysis
Part of: AI in Biotechnology Market (Global)

The UK AI in Biotechnology Market was valued at $517.5 Million in 2030 and projected to reach to $1279.5 Million by 2035, representing a compound annual growth rate of 20.1%. The UK AI in Biotechnology Market is poised for sustained growth through 2035, driven by increasing collaboration between academic institutions, biotech startups, and pharmaceutical companies leveraging AI for drug development and personalized medicine.

UK AI in Biotechnology Market (2030-2035) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK AI in Biotechnology Market Trends and Insights

  • The UK's strong position in life sciences research, combined with significant investment in artificial intelligence infrastructure, positions the country as a leading hub for AI-driven biotechnology innovation.
  • The UK's regulatory framework and concentration of biotech clusters in London, Cambridge, and Oxford are accelerating adoption of AI technologies across drug discovery, genomics, and personalized medicine. Driving the UK's 20.1% compound annual growth rate through 2035, the UK benefits from government funding initiatives, partnerships between academic institutions and industry, and a growing talent pool in computational biology.
  • The UK's commitment to precision medicine and its established pharmaceutical sector create substantial opportunities for AI integration.
  • By 2035, the UK AI in Biotechnology Market is expected to more than double, reflecting the country's strategic focus on becoming a global leader in AI-enabled life sciences innovation..

Key Market Statistics

  • CAGR (2030-2035) 20.1% CAGR
  • Market Size, 2030 ~USD 517.5 Million
  • Forecast, 2035 ~USD 1279.5 Million
  • Country UK

UK AI in Biotechnology Market Overview

Market Valuation Growth :

The UK AI in Biotechnology Market is valued at $517.5 million in 2030 and is projected to reach $1,279.5 million by 2035, representing a robust 20.1% CAGR over the forecast period.

Life Sciences Leadership :

The UK maintains a strong position as a global life sciences hub, with world-class research institutions and biotech clusters in Cambridge, Oxford, and London driving AI-powered innovation in drug discovery and genomics.

AI Infrastructure Investment :

Significant government and private sector investment in AI infrastructure, combined with the UK's regulatory sandbox approach, accelerates adoption of machine learning and deep learning technologies across biotechnology applications.

Regulatory Advantage :

The UK's progressive regulatory framework and post-Brexit agility enable faster approval pathways for AI-driven biotech solutions, positioning British companies competitively in the global market.

UK AI in Biotechnology Market Dynamics

  • The UK's commitment to life sciences as a strategic priority, coupled with substantial R&D funding and talent retention initiatives, will continue to attract global investment and foster innovation ecosystems. Key growth drivers include accelerating adoption of AI in clinical trials, genomic sequencing, and protein structure prediction.
  • The convergence of UK regulatory flexibility, strong intellectual property protections, and access to European and global markets positions the country as a preferred destination for AI-biotech ventures.
  • Emerging applications in precision medicine and biomarker discovery will further expand market opportunities through 2035..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • The UK AI in Biotechnology Market will grow from $517.5M (2030) to $1,279.5M (2035), representing a 20.1% CAGR.
      • The UK's established biotech hubs in Cambridge, Oxford, and London are driving concentrated AI adoption in drug discovery and genomics.
      • Government funding and academic-industry partnerships are accelerating AI integration across the UK's life sciences sector.
      • The UK's regulatory environment and precision medicine focus position it as a competitive hub for AI biotechnology innovation through 2035.

      AI in Biotechnology Market Report Scope

      Report Metric Details
      Base Year 2030
      Fastest Growing Segment DRUG DISCOVERY (Type)
      Forecast Period 2030–2035
      Growth Rate CAGR of 18.5% from 2030 to 2035
      Largest Segment CLOUD-BASED SOLUTIONS (Deployment Mode)
      Market Size Base Year (Billions) ~USD 9.72 (2030)
      Revenue Forecast (Billions) ~USD 22.72 (2035)
      Segments Covered Offering, Function, Type, Deployment Mode, End User

      UK AI in Biotechnology Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Offering

      • End-To-End Solutions
      • Niche Solutions
      • Services
      • Technologies
      • Technology

      By Function

      • Corporate
      • Launch & Commercial
      • Manufacturing & Supply Chain
      • Post-Marketing Surveillance & Patient Support
      • Regulatory Compliance
      • Research & Development

      By Type

      • Adverse Event Reporting
      • Biomarker Discovery
      • Clinical Data Assessment
      • Clinical Development
      • Compliance Monitoring
      • Consulting Services
      • Demand Forecasting
      • Drug Discovery
      • Hybrid Cloud
      • Implementation Services & Ongoing It Support
      • Inventory Management
      • Launch Coordination
      • Logistics Optimization
      • Marketing Operations
      • Medication Adherence
      • Molecular Design & Optimization
      • Monitoring & Drug Adherence
      • Multi Cloud
      • Other Corporate Functions
      • Other Manufacturing & Supply Chain Functions
      • Patient Engagement
      • Patient Monitoring
      • Patient Support Programs
      • Post-Sales & Maintenance Services
      • Predictive Maintenance
      • Predictive Pricing
      • Predictive Toxicity & Risk Monitoring
      • Private Cloud
      • Public Cloud
      • Real-World Evidence (Rwe) Analysis
      • Real-World Evidence(Rwe) Analysis
      • Recruitment
      • Risk Management
      • Sales Force Optimization
      • Site Selection
      • Structure-Activity Relationship (Sar) Modeling
      • Supply Chain Planning
      • Training & Education Services
      • Trial Design

      By Deployment Mode

      • Cloud-Based Solutions
      • On-Premises Solutions

      By End User

      • Biotechnology Companies
      • Clinical Research Organizations
      • Contract Research Organizations
      • Healthcare Providers
      • Pharmaceutical Companies
      • Research Institutes & Labs

      Target Audience

      • Pharmaceutical & Biotech Companies : UK and international pharma firms seeking to expand AI capabilities in drug discovery, clinical trials, and personalized medicine require detailed market intelligence to guide R&D investments and partnership decisions.
      • Venture Capital & Private Equity : Investment firms targeting the UK biotech sector need comprehensive market data, growth forecasts, and competitive landscapes to identify promising AI-biotech startups and optimize portfolio allocation.
      • AI & Software Technology Providers : Tech companies developing AI solutions for biotechnology applications require UK-specific market insights to tailor offerings, understand adoption barriers, and prioritize market entry strategies.
      • Government & Policy Makers : UK government agencies and policy bodies need market research to inform life sciences strategy, funding allocation, and regulatory frameworks supporting AI-biotech innovation and competitiveness.
      • Academic & Research Institutions : UK universities and research centers require market data to guide commercialization efforts, identify collaboration opportunities, and secure funding for AI-driven biotechnology research initiatives.

      Key Companies in the UK AI in Biotechnology Market

      CompanyHQOwnershipStrongest segments
      NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI Compute & Networking,Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Arrays and genotyping consumables,
      RECURSIONUnited StatesPublic CompanyPlatform collaboration and milestones,Internal pipeline R&D funding (capitalized/other income),Other services and data partnerships,
      SCHRöDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations (e.g., Novartis and others),Drug Discovery – Internal Pipeline,
      BENEVOLENTAIUnited KingdomPrivate CompanyAI discovery platform and licenses,Collaborative R&D projects and services,Custom data/ontology and analytics solutions,
      QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health, transplant, viral load),PCR and digital PCR instruments and consumables,
      TEMPUSUnited StatesPublic CompanyOncology NGS diagnostics (xT, xR, solid tumor and hematologic panels),Other diagnostics (PCR profiling, pathology, inherited conditions, pharmacogenomics nP),Data licensing and software (Insights, Lens, Hub, Next, Algos, Organoids, Trials),
      SOPHIA GENETICSSwitzerlandPublic CompanySOPHiA DDM platform subscriptions and usage-based analytics,Implementation, support, and workflow services,Biopharma collaborations and data-driven research solutions,
      PREDICTIVE ONCOLOGYUnited StatesPublic CompanyCompute Services and Treasury Management,Drug Discovery Services,
      XTALPI INC.ChinaPublic CompanyAI-driven drug discovery solutions (hit discovery, optimization, biology, PepiX),Computational software platforms (XFEP, XMolGen, PatSight, XtalGazer),Automation hardware and integrated workstations (XmartChem, ChemPlus),

      NVIDIA CORPORATION

      NVIDIA Corporation is a publicly traded technology company founded in 1993 and headquartered in the United States. With 42,000 employees, the company designs and manufactures graphics processing units and system-on-chip units. NVIDIA serves markets including gaming, professional visualization, data centers, and artificial intelligence.

      ILLUMINA, INC.

      Illumina, Inc. is a publicly traded genomics company founded in 1998 and based in the United States. The company employs 8,625 people and specializes in DNA sequencing and array-based technologies. Illumina's platforms are used for applications in research, clinical diagnostics, and precision medicine.

      RECURSION

      Recursion is a publicly traded biotechnology company founded in 2013 and headquartered in the United States. With 600 employees, the company uses machine learning and high-throughput biology to discover and develop therapeutics. Recursion focuses on identifying novel drug candidates through computational and experimental approaches.

      SCHRöDINGER, INC.

      Schrödinger, Inc. is a publicly traded computational chemistry and drug discovery company founded in 1990 and based in the United States. The company employs 850 people and develops software platforms for molecular simulation and drug design. Schrödinger's tools are used by pharmaceutical and biotechnology companies to accelerate drug development.

      BENEVOLENTAI

      BenevolentAI is a privately held artificial intelligence company founded in 2013 and headquartered in the United Kingdom. With 173 employees, the company applies machine learning and AI to drug discovery and development. BenevolentAI focuses on identifying new therapeutic targets and repurposing existing drugs for various diseases.

      QIAGEN

      QIAGEN is a publicly traded life sciences company founded in 1984 and headquartered in the Netherlands. With 5,500 employees, the company develops and manufactures sample preparation and molecular testing technologies. QIAGEN serves customers in molecular diagnostics, applied testing, and academic research.

      TEMPUS

      Tempus is a publicly traded artificial intelligence and precision medicine company founded in 2015 and based in the United States. With 3,800 employees, the company leverages machine learning and data analytics to improve cancer treatment and outcomes. Tempus analyzes clinical and molecular data to provide actionable insights for oncology care.

      SOPHIA GENETICS

      Sophia Genetics is a publicly traded digital health company founded in 2011 and headquartered in Switzerland. With 415 employees, the company develops AI-powered platforms for genomic data interpretation and clinical decision support. Sophia Genetics serves hospitals, diagnostic laboratories, and research institutions globally.

      PREDICTIVE ONCOLOGY

      Predictive Oncology is a publicly traded cancer diagnostics and treatment company founded in 2002 and based in the United States. With 14 employees, the company develops personalized medicine solutions for oncology patients. Predictive Oncology focuses on tumor profiling and treatment prediction technologies.

      XTALPI INC.

      XtalPi Inc. is a publicly traded artificial intelligence and drug discovery company founded in 2015 and headquartered in China. The company uses machine learning and computational chemistry to accelerate drug discovery and development. XtalPi focuses on molecular simulation and structure-based drug design.

      Reasons to Buy this Report

      • UK-Specific Market Sizing : Access precise valuation data and growth projections exclusive to the UK market, enabling accurate financial forecasting and investment decisions tailored to the British biotechnology landscape.
      • Competitive Intelligence : Identify key UK-based players, emerging startups, and institutional partnerships driving AI adoption in biotechnology, providing actionable insights for market positioning and partnership strategies.
      • Regulatory & Policy Insights : Understand the UK's unique regulatory environment, post-Brexit advantages, and government support mechanisms that differentiate opportunities from other European and global markets.
      • Investment Opportunity Assessment : Evaluate sector-specific growth drivers, funding trends, and venture capital activity within the UK AI-biotech ecosystem to identify high-potential investment and acquisition targets.
      • Strategic Market Entry Planning : Leverage UK-focused market analysis to develop go-to-market strategies, identify talent clusters, and navigate the regulatory pathway for launching AI-biotech solutions in Britain.

      Frequently asked questions

      What is the projected size of the UK AI in Biotechnology Market by 2035?

      The UK AI in Biotechnology Market is projected to reach $1,279.5 million by 2035, growing from $517.5 million in 2030.

      What is the CAGR for the UK AI in Biotechnology Market?

      The UK AI in Biotechnology Market is expected to grow at a compound annual growth rate of 20.1% between 2030 and 2035.

      Which UK cities are leading AI biotechnology innovation?

      The UK's primary biotech innovation hubs are Cambridge, Oxford, and London, where AI adoption is concentrated in drug discovery and genomics research.

      What factors are driving growth in the UK AI in Biotechnology Market?

      Key growth drivers include government funding initiatives, academic-industry partnerships, a growing computational biology talent pool, and the UK's focus on precision medicine.

      How does the UK AI in Biotechnology Market compare to other European markets?

      The UK's 20.1% CAGR reflects strong competitive positioning within Europe, supported by established regulatory frameworks and concentrated biotech infrastructure.

      RESEARCH METHODOLOGY

      This market research study primarily relied on secondary sources, directories, and databases to collect information for this technical, market-oriented, and financial analysis of the AI in biotechnology market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from major market players, and industry consultants, among others, to gather and verify critical qualitative and quantitative data and assess market prospects. The size of the AI in biotechnology market was estimated using multiple secondary research methods and confirmed with inputs from primary research to determine the final market size.

      Secondary Research

      The secondary research process involved extensively using secondary sources, including directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), Healthcare Information and Management Systems Society (HIMSS), Centers for Disease Control and Prevention (CDC), ClinicalTrials.gov, expert interviews, and MarketsandMarkets analysis.

      Secondary research was conducted to gather information for the detailed, technical, market-focused, and commercial analysis of the AI in biotechnology market. It was also used to collect key information about major players, market classification, and segmentation based on industry trends, down to the most detailed level, along with significant developments related to market and technology perspectives. Additionally, a database of leading industry players was compiled using secondary research.

      Primary Research

      During the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources mainly include industry experts from core and related industries, preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations involved in all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, among other specialists, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

      Primary research was conducted to identify segmentation types, industry trends, key players, and key market dynamics such as drivers, restraints, opportunities, challenges, and strategies adopted by key players.

      After completing the market engineering process- which includes calculations for market statistics, market breakdown, size estimations, forecasting, and data triangulation- extensive primary research was carried out. This research aimed to gather information and verify the key numbers obtained during the market analysis. Additionally, primary research was used to identify different types of market segmentation, analyze industry trends, evaluate the competitive landscape of AI solutions for biotechnology offered by various players, and understand key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies employed by key market players.

      In the complete market engineering process, the top-down and bottom-up approaches, along with several data triangulation methods, were extensively used to estimate and forecast the market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was conducted on the entire market engineering process to identify key information and insights throughout the report.

      Breakdown of Primary Interviews

      AI in Biotechnology Market

      Note 1: Others include sales, marketing, and product managers.

      Note 2: Tiers are defined based on a company’s total revenue, as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The market size estimates and forecasts in this study are based on a combination of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (evaluation of utilization, adoption, and penetration trends by offering, function, deployment mode, end user, and region).

      AI in Biotechnology Market

      Data Triangulation

      After determining the overall market size from the estimation process described above, the market for AI in biotechnology was divided into various segments and subsegments. To finalize the overall market analysis and obtain accurate statistics for all segments and subsegments, data triangulation and market breakdown techniques were used whenever applicable. The data was cross-verified by examining different factors and trends from both the demand and supply sides of the market for AI in biotechnology.

      Market Definition

      The AI in biotechnology market includes technologies that use artificial intelligence to advance drug discovery, genomics, and personalized medicine. This market is defined by the growing utilization of machine learning and data analytics to improve research and development efficiency.

      Stakeholders

      • Healthcare IT service providers
      • Pharmaceutical/Biopharmaceutical companies
      • Biotechnology firms
      • AI technology providers
      • Academic & research institutions
      • Academic medical centers/universities/hospitals
      • Regulatory agencies
      • Clinical research organizations (CROs)
      • Genomic testing labs
      • Government agencies
      • Startups in AI and biotech
      • Pharmaceutical supply chain partners
      • Consulting firms
      • Clinical trial management system providers
      • Bioinformatics companies
      • Advocacy groups
      • Investors & financial institutions

      Report Objectives

      • To define, describe, and forecast the AI in biotechnology market by offering, function, deployment mode, end user, and region
      • To provide detailed information regarding the major drivers, restraints, opportunities, and challenges influencing market growth
      • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall AI in biotechnology market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the AI in biotechnology market in five main regions (and their respective countries): North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To provide key industry insights, such as value chain, regulatory, patent, and recession impact analysis
      • To profile the key players in the market and comprehensively analyze their core competencies
      • To track and analyze competitive developments, such as product launches & upgrades, collaborations, partnerships, acquisitions, investments, contracts, agreements, alliances, mergers, funding, and expansions of the leading players in the market
      • To benchmark players within the market using the company evaluation matrix, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

      Get the Full AI in Biotechnology Market Report

      Full forecast, segment splits, and company analysis for all AI in Biotechnology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status